Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma (Q44115428)

29 November 2017

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma (English)

1 reference

29 November 2017

phase II clinical trial

0 references

1 reference

Keith M Skubitz

1

1 reference

29 November 2017

1 January 2002

1 reference

29 November 2017

1 reference

29 November 2017

20

1 reference

29 November 2017

5-6

1 reference

29 November 2017

693-699

1 reference

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

29 November 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

Caelyx in malignant mesothelioma: a phase II EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003538

21 January 2018

Identifiers

DOI

10.1081/CNV-120003538

1 reference

release_anv4tb4lira7pctzh7sbzf5xpy

29 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/anv4tb4lira7pctzh7sbzf5xpy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12197225

1 reference

PubMed ID

12197225